ArticlePloS one2025
Serum uric acid level as a prognostic biomarker in critically ill patients with sepsis-associated acute kidney injury: A retrospective single-center study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on the correlation between gut microbiota and the occurrence of hyperuricemia.Frontiers in microbiology · 2026Review
- Nonlinear Associations of Uric Acid and Mitochondrial DNA with Mortality in Critically Ill Patients.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe predictive value of serum uric acid (SUA) for clinical outcomes in patients with sepsis-associated acute kidney injury (SA-AKI) remained unclear. Therefore, this study aimed to evaluate the clinical significance of SUA in predicting all-cause mortality among critically ill patients diagnosed with SA-AKI.
methodsThis retrospective study examined 483 patients with SA-AKI at the Affiliated Hospital of Jiangsu University from January 2015 to July 2023. The primary outcome evaluated in this study was in hospital all-cause mortality. To assess the prognostic value of SUA, we employed receiver operating characteristic curves, restricted cubic splines, Cox regression models, and Kaplan-Meier survival analysis.
resultsThe hospital mortality and intensive care unit (ICU) mortality reached 43.3% and 42.2%, respectively. Kaplan-Meier analysis showed that the risk of 30-day mortality (log-rank test, P < 0.001) and 60-day mortality (log-rank test, P = 0.001) was significantly higher in patients with hyperuricemia (HUA). Multivariate Cox proportional hazards analysis showed that elevated SUA levels were significantly related to all-cause mortality. After accounting for potential confounding factors, patients with HUA maintained a significant correlation with both hospital mortality [HR (95%CI): 1.462 (1.094-1.952); P = 0.010] and ICU mortality [HR (95%CI): 1.474 (1.096-1.983); P = 0.010]. Further examination using restricted cubic splines revealed a progressively increasing risk of all-cause mortality with rising SUA levels.
conclusionsHigher levels of SUA were associated with an increased risk of both hospital mortality and ICU mortality in critically ill patients with SA-AKI. These findings suggested that SUA may serve as an independent prognostic marker for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.